Back

Climb Bio reports 29-day projected half-life for CLYM116 in Phase 1

Verifying
  • Climb Bio released preliminary Phase 1 data for subcutaneous CLYM116.
  • 46 healthy volunteers received single-ascending or multiple-ascending doses in the trial.
  • Climb Bio is conducting NAVIGATE-2 Phase 2 testing in IgA nephropathy.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.